Barclays
DMRA

Barclays’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Barclays’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$571K Buy
+22,034
New +$566K ﹤0.01% 3115
2025
Q4 		– Sell
-55
Closed -$205 – 5397
2025
Q3 		$205 Sell
55
-45
-45% -$152 ﹤0.01% 5241
2025
Q2 		$341 Sell
100
-33
-25% -$98 ﹤0.01% 5087
2025
Q1 		$412 Buy
+133
New +$627 ﹤0.01% 5091

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RCP
Remedium Capital Partners Fort Lauderdale, Florida $281M AUM

Barclays's DMRA Position: Q1 2026 in Review

Barclays opened a new position in Damora Therapeutics, Inc. Ordinary Shares (DMRA) in Q1 2026: 22,034 shares worth $571K. The stake represents ﹤0.01% of the portfolio and ranks #3115 among its holdings. This is a return to the name: Barclays previously reported a position in DMRA as recently as Q3 2025.

Barclays first reported a position in DMRA in Q1 2025 and has held it in 4 quarters since. 65 funds tracked by Wall St. Rank hold DMRA as of Q1 2026.

  • Barclays held 22,034 shares of Damora Therapeutics, Inc. Ordinary Shares worth $571K as of Q1 2026.
  • Damora Therapeutics, Inc. Ordinary Shares was a new Barclays position in Q1 2026.
  • Damora Therapeutics, Inc. Ordinary Shares made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3115 holding.
  • Barclays first reported a position in Damora Therapeutics, Inc. Ordinary Shares in Q1 2025 and has held it in 4 quarters since.
  • 65 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.